AurélieCamard

Counsel

パリ + 33.1.56.59.46.04

Connect:

共有

Aurélie Camard's practice focuses on private, domestic, and cross-border M&A transactions, advising French and foreign clients on acquisitions, divestments, mergers, carve-outs, strategic alliances, and joint ventures. Aurélie's practice also includes general corporate and contractual law matters.

Aurélie has represented clients in various industries for more than 10 years, notably in the energy, manufacturing, new technologies, health care, life sciences, and financial services sectors.

In the energy sector, Aurélie has advised TotalEnergies on several projects. She also regularly represents Sanofi, one of the French leading pharmaceutical companies, in the divestment of product portfolios.

In addition, Aurélie has significant experience in the defense, life sciences, and services sectors, advising clients on a wide range of M&A and corporate law matters.

担当案件

  • Sanofi sells two established product portfolios to NeuraxpharmJones Day advised Sanofi in the sale of 2 portfolios of products for central nervous systems disorders and pain and vascular diseases to LESVI, a Spanish subsidiary of Neuraxpharm.
  • Électricité de Strasbourg forms JV with ErametJones Day advised Électricité de Strasbourg, an energy provider in Alsace (France), in the formation of a joint venture with Eramet, one of the leading French actors in the mining and metallurgy industries, to develop and use joint capabilities for the extraction, refining and production of lithium from geothermal resources, with a targeted annual volume of 10,000 tons of lithium corresponding to the volume necessary to produce c.250,000 batteries for electric vehicles per year).
  • Timken acquires GGB Bearing Technology for $305 millionJones Day advised The Timken Company in the $305 million acquisition of GGB Bearing Technology (GGB), a division of Enpro, Industries (including exclusive negotiations with respect to the French operations of GGB).
  • Diebold Nixdorf successfully restructures over $2.7 billion in funded debt and completes the first-ever dual proceeding under the U.S. bankruptcy code and Dutch restructuring law in 71 daysIn the first-ever cross border restructuring involving dual main proceedings under chapter 11 of the U.S. Bankruptcy Code and a scheme of arrangement (the "Dutch Scheme") under the Dutch Act on Confirmation of Extrajudicial Plans (Wet Homologatie Onderhands Akkoord ("WHOA")), and the first-ever chapter 15 recognition of Dutch Scheme proceedings and a sanctioned WHOA reorganization plan (the "WHOA Plan"), Jones Day represented Diebold Nixdorf, Incorporated ("Diebold") and certain of its U.S. and Canadian subsidiaries (the "Debtors") in connection with (i) the prepackaged chapter 11 cases of In re Diebold Holding Company, LLC, et al., (Case No. 23-90602-DRJ) commenced on June 1, 2023, in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"); (ii) the Dutch Scheme, commenced on June 1, 2023 by Diebold Nixdorf Dutch Holding B.V. (the "Dutch Issuer") in the District Court of Amsterdam (the "Dutch Court"), and (iii) the chapter 15 proceedings before the Bankruptcy Court commenced by the foreign representative of the Dutch Issuer, wherein the Bankruptcy Court recognized the Dutch Scheme proceeding as a foreign main proceeding and recognized and extended comity to the WHOA Plan that was sanctioned by the Dutch Court.
    •

    送信する前の注意事項：

    www.jonesday.comに掲載されている情報は、一般的な使用を目的としており、法的アドバイスを目的としたものではありません。このEmailを送信することにより、弁護士を含む専門家・依頼者の関係を構築することを意図するものではなく、このEmailの受領はそのような関係を構築するものではありません。当事務所に送信されたいかなる情報も、業務委託契約を結ばない限り、弁護士等が依頼者に対して守秘義務を負う機密事項として取り扱われることはありません。このEmailの送信者は以上の注意事項の内容を読み、理解したものと判断します。